148 related articles for article (PubMed ID: 12704416)
1. Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose.
Haberkorn U; Kinscherf R; Kissel M; Kübler W; Mahmut M; Sieger S; Eisenhut M; Peschke P; Altmann A
Gene Ther; 2003 May; 10(9):774-80. PubMed ID: 12704416
[TBL] [Abstract][Full Text] [Related]
2. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells.
Haberkorn U; Beuter P; Kübler W; Eskerski H; Eisenhut M; Kinscherf R; Zitzmann S; Strauss LG; Dimitrakopoulou-Strauss A; Altmann A
J Nucl Med; 2004 May; 45(5):827-33. PubMed ID: 15136633
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy with sodium/iodide symporter in hepatocarcinoma.
Haberkorn U
Exp Clin Endocrinol Diabetes; 2001; 109(1):60-2. PubMed ID: 11573143
[TBL] [Abstract][Full Text] [Related]
4. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
Kakinuma H; Bergert ER; Spitzweg C; Cheville JC; Lieber MM; Morris JC
Cancer Res; 2003 Nov; 63(22):7840-4. PubMed ID: 14633711
[TBL] [Abstract][Full Text] [Related]
5. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
6. Tumour-specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3).
Sieger S; Jiang S; Schönsiegel F; Eskerski H; Kübler W; Altmann A; Haberkorn U
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):748-56. PubMed ID: 12541134
[TBL] [Abstract][Full Text] [Related]
7. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene.
Chen L; Altmann A; Mier W; Eskerski H; Leotta K; Guo L; Zhu R; Haberkorn U
J Nucl Med; 2006 May; 47(5):854-62. PubMed ID: 16644756
[TBL] [Abstract][Full Text] [Related]
9. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas.
Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM
Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377
[TBL] [Abstract][Full Text] [Related]
10. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells.
Haberkorn U; Henze M; Altmann A; Jiang S; Morr I; Mahmut M; Peschke P; Kübler W; Debus J; Eisenhut M
J Nucl Med; 2001 Feb; 42(2):317-25. PubMed ID: 11216532
[TBL] [Abstract][Full Text] [Related]
11. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids.
Mitrofanova E; Hagan C; Qi J; Seregina T; Link C
Anticancer Res; 2003; 23(3B):2397-404. PubMed ID: 12894520
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
Carlin S; Akabani G; Zalutsky MR
J Nucl Med; 2003 Nov; 44(11):1827-38. PubMed ID: 14602867
[TBL] [Abstract][Full Text] [Related]
13. Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.
Klutz K; Russ V; Willhauck MJ; Wunderlich N; Zach C; Gildehaus FJ; Göke B; Wagner E; Ogris M; Spitzweg C
Clin Cancer Res; 2009 Oct; 15(19):6079-86. PubMed ID: 19789324
[TBL] [Abstract][Full Text] [Related]
14. Expression of the human sodium/iodide symporter (hNIS) in xenotransplanted human thyroid carcinoma.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Romijn JA; van der Heide D
Exp Clin Endocrinol Diabetes; 2001; 109(1):52-5. PubMed ID: 11573141
[TBL] [Abstract][Full Text] [Related]
15. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line.
Smit JW; Schröder-van der Elst JP; Karperien M; Que I; Stokkel M; van der Heide D; Romijn JA
J Clin Endocrinol Metab; 2002 Mar; 87(3):1247-53. PubMed ID: 11889195
[TBL] [Abstract][Full Text] [Related]
16. In vivo sodium iodide symporter gene therapy of prostate cancer.
Spitzweg C; Dietz AB; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Gene Ther; 2001 Oct; 8(20):1524-31. PubMed ID: 11704812
[TBL] [Abstract][Full Text] [Related]
17. Rat sodium iodide symporter for radioiodide therapy of cancer.
Mitrofanova E; Unfer R; Vahanian N; Daniels W; Roberson E; Seregina T; Seth P; Link C
Clin Cancer Res; 2004 Oct; 10(20):6969-76. PubMed ID: 15501976
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus.
Lee WW; Lee B; Kim SJ; Jin J; Moon DH; Lee H
Oncol Rep; 2003; 10(4):845-9. PubMed ID: 12792733
[TBL] [Abstract][Full Text] [Related]
19. Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells.
Schipper ML; Weber A; Béhé M; Göke R; Joba W; Schmidt H; Bert T; Simon B; Arnold R; Heufelder AE; Behr TM
Cancer Res; 2003 Mar; 63(6):1333-8. PubMed ID: 12649195
[TBL] [Abstract][Full Text] [Related]
20. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
